857064-38-1 | (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-n-(1-phenylethyl)acrylamide

Packsize	Purity	Availability	Price	Discounted Price
25mg	98%(HPLC)	in stock	$31.00	$22.00
100mg	98%(HPLC)	in stock	$91.00	$64.00
250mg	98%(HPLC)	in stock	$151.00	$106.00
1g	98%	in stock	$226.00	$158.00

Description

• Catalog Number: AC32567
• Chemical Name: (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-n-(1-phenylethyl)acrylamide
• CAS Number: 857064-38-1
• Molecular Formula: C17H14BrN3O
• Molecular Weight: 356.2166
• MDL Number: MFCD12912450
• SMILES: N#C/C(=C\c1cccc(n1)Br)/C(=O)N[C@H](c1ccccc1)C

Computed Properties

• Complexity: 462
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 22
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 3.4

Literature

• Molecular mechanisms of 3,3'4,4',5-pentachlorobiphenyl-induced epithelial-mesenchymal transition in human hepatocellular carcinoma cells.

  Toxicology and applied pharmacology 20170501

• The evaluation of p,p'-DDT exposure on cell adhesion of hepatocellular carcinoma.

  Toxicology 20140801

• Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.

  The Journal of biological chemistry 20140502

• Cucurbitacin B and cucurbitacin I suppress adipocyte differentiation through inhibition of STAT3 signaling.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20140201

• Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation.

  Basic research in cardiology 20120501

• Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma.

  Bioorganic & medicinal chemistry 20111201

• Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.

  Oncology reports 20111101

• Lysophosphatidic acid induces erythropoiesis through activating lysophosphatidic acid receptor 3.

  Stem cells (Dayton, Ohio) 20111101

• STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.

  British journal of cancer 20100525

• WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080201

• WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.

  Cancer research 20071201

• A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.

  Oncogene 20070412